high grade glioma (Cancer)
Information
- Disease name
- high grade glioma
- Disease ID
- DOID:3070
- Description
- "A cell type cancer that has_material_basis_in glial cells and is located in brain or located in spine." [url:http\://en.wikipedia.org/wiki/Malignant_glioma]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| RHBDF2 | 17 | 76,470,896 | 76,501,407 | 2 |
| FBXO11 | 2 | 47,806,920 | 47,906,498 | 2 |
| FANCI | 15 | 89,244,017 | 89,317,080 | 2 |
| SMARCA4 | 19 | 10,961,001 | 11,062,256 | 2 |
| ATM | 11 | 108,222,804 | 108,369,102 | 2 |
| BUB1B | 15 | 40,161,069 | 40,221,123 | 2 |
| ERCC3 | 2 | 127,257,290 | 127,294,144 | 2 |
| MSH2 | 2 | 47,403,156 | 47,483,223 | 2 |
| MSH6 | 2 | 47,783,145 | 47,806,953 | 2 |
| CFTR | 7 | 117,480,025 | 117,668,665 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05362409 | Active, not recruiting | Phase 1 | Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma | June 29, 2022 | April 30, 2025 |
| NCT04911621 | Active, not recruiting | Phase 1/Phase 2 | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma | September 10, 2021 | June 1, 2027 |
| NCT03334305 | Active, not recruiting | Phase 1 | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas | May 16, 2018 | May 2028 |
| NCT05023551 | Active, not recruiting | Early Phase 1 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | September 8, 2021 | July 31, 2024 |
| NCT02655601 | Active, not recruiting | Phase 2 | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 | September 25, 2018 | December 2024 |
| NCT04865315 | Active, not recruiting | A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors | May 1, 2022 | December 2024 | |
| NCT03605550 | Active, not recruiting | Phase 1 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | August 1, 2018 | March 1, 2029 |
| NCT03128047 | Active, not recruiting | Phase 1 | HUMC 1612: Optune NovoTTF-200A System | April 6, 2017 | June 2024 |
| NCT01390948 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | October 18, 2011 | January 29, 2020 |
| NCT01403610 | Completed | Phase 2 | Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab | June 2011 | October 2015 |
| NCT01466686 | Completed | Phase 2 | Low Dose Radiation Therapy for Glioblastoma Multiforme | September 2012 | December 2022 |
| NCT01808820 | Completed | Phase 1 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | August 21, 2013 | July 16, 2022 |
| NCT02022644 | Completed | Phase 1 | Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma | October 23, 2014 | May 31, 2023 |
| NCT02041611 | Completed | N/A | Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas | July 13, 2012 | December 17, 2015 |
| NCT03925246 | Completed | Phase 2 | Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas | July 30, 2019 | August 18, 2021 |
| NCT03775369 | Completed | N/A | Glioma and Exercising | October 26, 2018 | February 28, 2022 |
| NCT03355794 | Completed | Phase 1 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | November 14, 2017 | July 31, 2022 |
| NCT00561873 | Completed | Nimotuzumab in Children With HGG | June 2004 | February 2007 | |
| NCT00589875 | Completed | Phase 2 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | March 2007 | August 2016 |
| NCT00780819 | Completed | N/A | Borderzone Sampling | October 2008 | December 2012 |
| NCT00897611 | Completed | N/A | Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma | April 2005 | |
| NCT01191346 | Completed | Radiation Planning Study for High Grade Brain Tumors | June 2010 | March 2013 | |
| NCT01222754 | Completed | Phase 1 | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | November 23, 2010 | April 17, 2019 |
| NCT01240161 | Completed | Personalized Translational Platform for Biomarker Discovery in Brain Tumors | December 2009 | March 2016 | |
| NCT04289155 | No longer available | Individual Patient Compassionate Use of GX-I7 | |||
| NCT04254419 | Not yet recruiting | Phase 1 | Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas | December 2023 | October 2025 |
| NCT04482933 | Not yet recruiting | Phase 2 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | June 3, 2024 | February 1, 2029 |
| NCT05096481 | Not yet recruiting | Phase 2 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | June 15, 2024 | June 15, 2030 |
| NCT05839379 | Not yet recruiting | Targeted Pediatric High-Grade Glioma Therapy | May 30, 2024 | May 30, 2034 | |
| NCT05843253 | Not yet recruiting | Phase 2 | Study of Ribociclib and Everolimus in HGG and DIPG | May 30, 2024 | May 30, 2034 |
| NCT05850377 | Not yet recruiting | 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas | June 1, 2023 | May 31, 2026 | |
| NCT06161974 | Not yet recruiting | Phase 2 | Study of Olutasidenib and Temozolomide in HGG | June 2024 | June 2035 |
| NCT06333899 | Not yet recruiting | Early Phase 1 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | September 1, 2024 | September 1, 2034 |
| NCT06357377 | Not yet recruiting | Phase 1 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | May 1, 2024 | October 31, 2024 |
| NCT06428045 | Not yet recruiting | Phase 1 | STARLITE for Unresectable High-Grade Gliomas | August 31, 2024 | May 31, 2029 |
| NCT05630664 | Recruiting | Liquid Biopsy in High-grade Gliomas and Meningiomas | October 1, 2022 | September 30, 2025 | |
| NCT05632562 | Recruiting | Early Phase 1 | Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma | March 7, 2024 | December 31, 2025 |
| NCT05644080 | Recruiting | N/A | 68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma | March 28, 2023 | December 2025 |
| NCT05773326 | Recruiting | Early Phase 1 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | May 15, 2023 | April 30, 2026 |
| NCT05835687 | Recruiting | Phase 1 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | April 27, 2023 | March 2028 |
| NCT06072586 | Recruiting | Early Phase 1 | Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions | October 18, 2023 | October 31, 2025 |
| NCT06264388 | Recruiting | Phase 2 | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | May 1, 2024 | May 1, 2034 |
| NCT06215495 | Recruiting | N/A | A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial | February 18, 2024 | June 1, 2027 |
| NCT04209790 | Recruiting | Phase 2 | Neoadjuvant Chemoradiation for Resectable Glioblastoma | April 1, 2020 | December 31, 2026 |
| NCT05979064 | Recruiting | N/A | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | April 4, 2023 | April 2027 |
| NCT04485559 | Recruiting | Phase 1 | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | December 9, 2020 | December 31, 2027 |
| NCT04559685 | Recruiting | Early Phase 1 | Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma | March 15, 2021 | March 31, 2025 |
| NCT03952598 | Recruiting | N/A | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy | October 16, 2019 | December 31, 2025 |
| NCT04655404 | Recruiting | Early Phase 1 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | April 8, 2021 | December 1, 2025 |
| NCT04734444 | Recruiting | N/A | SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue | September 1, 2021 | January 1, 2024 |
| NCT04737577 | Recruiting | N/A | Glioma Supra Marginal Incision Trial | February 5, 2021 | February 2025 |
| NCT04766632 | Recruiting | N/A | Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas | May 18, 2021 | March 12, 2025 |
| NCT04099797 | Recruiting | Phase 1 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | February 3, 2020 | February 2039 |
| NCT03411408 | Recruiting | N/A | Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma. | February 22, 2018 | May 2024 |
| NCT02970448 | Recruiting | Early Phase 1 | Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas | August 24, 2017 | June 1, 2024 |
| NCT03340506 | Recruiting | Phase 4 | Dabrafenib and/or Trametinib Rollover Study | December 28, 2017 | December 21, 2027 |
| NCT06016452 | Recruiting | Phase 2 | A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma | November 13, 2023 | November 2025 |
| NCT05212272 | Recruiting | MRI in High-Grade Glioma Patients Undergoing Chemoradiation | September 2, 2022 | December 2024 | |
| NCT05278208 | Recruiting | Phase 1/Phase 2 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | November 21, 2022 | November 2027 |
| NCT05298995 | Recruiting | Phase 1 | GD2-CAR T Cells for Pediatric Brain Tumours | November 9, 2023 | November 2038 |
| NCT05954858 | Recruiting | N/A | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | June 29, 2023 | June 30, 2026 |
| NCT05925218 | Recruiting | Circulating Tumor DNA Collection From Patients With High Grade Gliomas | September 2, 2022 | September 30, 2024 | |
| NCT05553041 | Recruiting | Early Phase 1 | 18F-Fluciclovine PET-MRI in High-grade Glioma | August 7, 2023 | December 2026 |
| NCT05565118 | Recruiting | Phase 1 | Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression | April 9, 2024 | January 1, 2026 |
| NCT02607124 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | April 2016 | August 2018 |
| NCT03971734 | Terminated | Phase 1 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | December 6, 2019 | October 2, 2023 |
| NCT03973918 | Terminated | Phase 2 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG | July 29, 2019 | October 1, 2023 |
| NCT00003535 | Terminated | Phase 2 | Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma | April 1994 | January 1998 |
| NCT02500459 | Terminated | Early Phase 1 | Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection | July 6, 2015 | November 19, 2018 |
| NCT04608812 | Terminated | Phase 1 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | March 2, 2021 | February 27, 2023 |
| NCT01902771 | Terminated | Phase 1 | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | September 3, 2013 | January 26, 2017 |
| NCT00826930 | Terminated | Phase 1 | Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma | March 2009 | May 2009 |
| NCT03352427 | Terminated | Phase 2 | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations | December 6, 2017 | May 15, 2019 |
| NCT03690869 | Terminated | Phase 1/Phase 2 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | September 24, 2018 | May 10, 2023 |
| NCT02885324 | Terminated | Phase 2 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | May 18, 2017 | August 25, 2020 |
| NCT05375318 | Unknown status | BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels | March 1, 2021 | July 1, 2022 | |
| NCT03294434 | Unknown status | Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study) | March 2, 2017 | September 30, 2022 | |
| NCT03392545 | Unknown status | Phase 1 | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1) | April 1, 2018 | June 1, 2020 |
| NCT01499823 | Unknown status | Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma | December 2011 | December 2013 | |
| NCT04267146 | Unknown status | Phase 1/Phase 2 | Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma | July 15, 2019 | January 2024 |
| NCT05082493 | Withdrawn | Phase 1 | A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas | December 2023 | December 30, 2023 |
| NCT00469534 | Withdrawn | N/A | Minimized Time to Beam in Patients With High Grade Gliomas | ||
| NCT04220892 | Withdrawn | Early Phase 1 | Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | July 8, 2020 | July 8, 2020 |
- Disase is a (Disease Ontology)
- DOID:0050687
- Cross Reference ID (Disease Ontology)
- ICDO:9380/3
- Cross Reference ID (Disease Ontology)
- KEGG:05214
- Cross Reference ID (Disease Ontology)
- MESH:D005910
- Cross Reference ID (Disease Ontology)
- MIM:PS137800
- Cross Reference ID (Disease Ontology)
- NCI:C3059
- Cross Reference ID (Disease Ontology)
- NCI:C4822
- Cross Reference ID (Disease Ontology)
- ORDO:182067
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:393564001
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:74532006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0017638
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0555198
- Exact Synonym (Disease Ontology)
- glial cell tumor
- Exact Synonym (Disease Ontology)
- glioma, malignant
- Exact Synonym (Disease Ontology)
- malignant glioma
- Exact Synonym (Disease Ontology)
- malignant Neuroglial tumor
- Exact Synonym (Disease Ontology)
- Neuroglial tumor